Clinical details of patients with ICC
| Year | P value | |||
| Prepandemic (March 2019–February 2020) | Pandemic (March 2020–February 2021) | |||
| Cases diagnosed | 76 | 64 | ||
| Mode of presentation | Surveillance | 6 (8%) | 1 (2%) | p=0.130 |
| Incidental | 12 (16%) | 13 (20%) | ||
| Symptomatic | 58 (76%) | 50 (78%) | ||
| TNM stage | I | 2 (3%) | 0 (0%) | p=0.002** |
| II | 19 (25%) | 3 (5%) | ||
| III | 12 (16%) | 8 (12%) | ||
| IV | 42 (56%) | 53 (83%) | ||
| Age in years (median) | 68.69±1.33 (71) | 70.22±1.30 (72) | p=0.518 | |
| Gender | Male | 46 (61%) | 42 (66%) | p=0.534 |
| Female | 30 (39%) | 22 (33%) | ||
| Performance status | 0 | 19 (25%) | 13 (20%) | p=0.659 |
| 1 | 31 (41%) | 31 (48%) | ||
| 2 | 19 (25%) | 12 (19%) | ||
| 3 | 7 (9%) | 7 (11%) | ||
| 4 | 0 (0%) | 1 (2%) | ||
| Tumour diameter in mm (median) | 57.54±5.72 (50) | 51.34±4.34 (42) | p=0.755 | |
| First-line treatment received | OLTx | 1 (1%) | 0 (0%) | p=0.261 |
| Resection | 14 (19%) | 10 (16%) | ||
| Ablation | 1 (1%) | 0 (0%) | ||
| TACE | 0 (0%) | 2 (3%) | ||
| SIRT | 3 (4%) | 0 (0%) | ||
| Medical | 20 (26%) | 14 (23%) | ||
| Supportive Care | 37 (49%) | 36 (58%) | ||
Continuous data are shown as mean±SE of mean, with median in parentheses. Categorical datasets have been analysed by Pearson’s χ2 tests, with p values for continuous data determined by t-test or Mann-Whitney U tests.
*p<0.05; **p<0.005.
ICC, intrahepatic cholangiocarcinoma; OLTx, orthotopic liver transplantation; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolisation; TNM, tumour-node-metastases.